WO-A1-2010/084999 (B1)

YANG JIAXING, ZHU LIN, CAI YONG, SUO JIAN, JIN JINGJI: "Role of downregulation of galectin-9 in the tumorigenesis of gastric cancer", INTERNATIONAL JOURNAL OF ONCOLOGY, DEMETRIOS A. SPANDIDOS ED. & PUB, GR, vol. 45, no. 3, 1 September 2014 (2014-09-01), GR, pages 1313 - 1320, ISSN: 1019-6439, DOI: 10.3892/ijo.2014.2494 (B2)

AERTS JOACHIM G., HEGMANS JOOST P.: "Tumor-Specific Cytotoxic T Cells Are Crucial for Efficacy of Immunomodulatory Antibodies in Patients with Lung Cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 73, no. 8, 15 April 2013 (2013-04-15), US, pages 2381 - 2388, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-12-3932 (B2)

AKIMOVA TATIANA, HANCOCK WAYNE W.: "How little is known about the role of human FOXP3+ Tregs in tumors", EXPERT OPINION ON THERAPEUTIC TARGETS, INFORMA HEALTHCARE, UK, vol. 22, no. 8, 3 August 2018 (2018-08-03), UK , pages 655 - 658, ISSN: 1472-8222, DOI: 10.1080/14728222.2018.1499728 (B2)

ANDREA LADÁNYI: "A tumort infiltráló immunsejtek prognosztikai értéke melanómában", MAGYAR ONKOLÓGIA, 1 January 2013 (2013-01-01), pages 85 - 95, Retrieved from the Internet <URL:https://huon.hu/2013/57/2/0085/0085a.pdf> [retrieved on 20210511] (B2)

AVALOS-MARTINEZ CLAUDIA E: "Measurement of suppressor activity of T CD 4+ CD 25+ T reg cells using bromodeoxyuridine incorporation assay", IMMUNOL INVEST., vol. 42, no. 4, 1 January 2013 (2013-01-01), pages 369 - 381 (B2)

BARJON ET AL.: "A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses", INFECTIOUS AGENTS AND CANCER, vol. 7, no. 1, 2012, pages 1 - 11, DOI: 10.1186/1750-9378-7-16 (B2)

BARJON: "Caractérisation biochimique et fonctionnelle de nouveaux anticorps monoclonaux anti-galectine-9 en vue d'applications diagnostiques et thérapeutiques", THÈSE DE DOCTORAT EN CANCÉROLOGIE, IMMUNOLOGIE, BIOLOGIE CELLULAIRE, BIOCHIMIE, 5 February 2013 (2013-02-05), pages 1 - 128 (B2)

Binding experiments with anti- Gal- 9 antibodies (B2)

CEDENO-LAURENT ET AL.: "Galectins and their ligands: negative regulators of anti-tumor immunity", GLYCOCONJ J., vol. 29, no. 8-9, 2012, pages 619 - 625, DOI: 10.1007/s10719-012-9379-0 (B2)

CLÉMENT BARJON ET AL: "A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses", INFECTIOUS AGENTS AND CANCER, BIOMED CENTRAL LTD, LO, vol. 7, no. 1, 17 July 2012 (2012-07-17), pages 16, XP021116920, ISSN: 1750-9378, DOI: 10.1186/1750-9378-7-16 (B2)

CUELLAR LUIS ERNESTO ET AL: "Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: a Peruvian experience", INFECTIOUS AGENTS AND CANCER, vol. 13, no. 1, 1 December 2018 (2018-12-01), DOI: 10.1186/s13027-018-0200-y (B2)

Comparative tests filed by the Patentees Prior to grant (B2)

Database references confirming that the Barjon Doctoral Thesis was published in 2013 (B2)

English translation of D27 (machine translation by google translate) (B2)

Evidence that 1G3 was commercially available at least by May 2015 (B2)

FUJIHARA ET AL.: "Galectin-9 in Cancer Therapy", RECENT PAT ENDOCR METAB IMMUNE DRUG DISCOV., vol. 7, no. 2, 2013, pages 130 - 7, DOI: 10.2174/1872214811307020006 (B2)

FUJITA KOJI, ET AL: "Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo", INTERNATIONAL JOURNAL OF ONCOLOGY, DEMETRIOS A. SPANDIDOS ED. & PUB, GR, vol. 46, no. 6, 1 June 2015 (2015-06-01), GR, pages 2419 - 2430, ISSN: 1019-6439, DOI: 10.3892/ijo.2015.2941 (B2)

GOODEN M J M, DE BOCK G H, LEFFERS N, DAEMEN T, NIJMAN H W: "The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 105, no. 1, 1 June 2011 (2011-06-01), GB, pages 93 - 103, ISSN: 0007-0920, DOI: 10.1038/bjc.2011.189 (B2)

HASSEN KARED, FABRE THOMAS, BÉDARD NATHALIE, BRUNEAU JULIE, SHOUKRY NAGLAA H.: "Galectin-9 and IL-21 Mediate Cross-regulation between Th17 and Treg Cells during Acute Hepatitis C", PLOS PATHOGENS, vol. 9, no. 6, pages e1003422 - e1003422-18, DOI: 10.1371/journal.ppat.1003422 (B2)

HEUSSCHEN ROY, ET AL: "Galectin-9 in tumor biology: A jack of multiple trades", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - REVIEWS ON CANCER, vol. 1836, 1 January 2013 (2013-01-01), pages 177 - 185 (B2)

IDS tiled by Patentee in the US admitting that the Barjon Doctoral Thesis was published in 2013 (B2)

IRIE ET AL.: "Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer", CLIN CANCER RES., vol. 11, no. 8, 2005, pages 2962 - 8, DOI: 10.1158/1078-0432.CCR-04-0861 (B2)

JIANG JING, ET AL: "Decreased Galectin-9 and Increased Tim-3 Expression Are Related to Poor Prognosis in Gastric Cancer", PLOS ONE, vol. 8, no. 12, 1 December 2013 (2013-12-01), pages e81799, DOI: 10.1371/journal.pone.0081799 (B2)

JU ET AL.: "The Tim-3/galectin-9 pathway involves in the homeostasis of hepatic Tregs in a mouse model of concanavalin A-induced hepatitis", MOLECULAR IMMUNOLOGY, vol. 58, no. 1, 2014, pages 85 - 91, DOI: 10.1016/j.molimm.2013.11.001 (B2)

KADOWAKI ET AL.: "Galectin-9 prolongs the survival of septic mice by expanding tim-3-expressing natural killer T cells and PDCA-1+ CDllc+macrophages", CRIT CARE, vol. 17, no. 6, 2013, pages 1 - 11, DOI: 10.1186/cc13147 (B2)

KADOWAKI TAKESHI ET AL: "Galectin-9 signaling prolongs survival in murine lung-cancer by inducing macrophages to differentiate into plasmacytoid dendritic cell-like macrophages", CLINICAL IMMUNOLOGY, vol. 142, no. 3, 2012, pages 296 - 307, XP028898525, ISSN: 1521-6616, DOI: 10.1016/J.CLIM.2011.11.006 (B2)

KLIBI ET AL.: "Blood diffusion and Th 1-suppressive effects of galectin-9- containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells", BLOOD, vol. 113, no. 9, 2009, pages 1957 - 66, DOI: 10.1182/blood-2008-02- (B2)

KOBAYASHI T, ET AL: "Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways", LEUKEMIA, STOCKTON PRESS, LONDON, vol. 24, no. 4, 1 April 2010 (2010-04-01), London, pages 843 - 850, ISSN: 0887-6924, DOI: 10.1038/leu.2010.25 (B2)

LHUILLIER: "Characterization of neutralizing antibodies reacting with the 213-224 amino-acid segment of human galectin-9", PLOS ONE, vol. 13, no. 9, 2018, pages 1 - 23, DOI: 10.1371/journal.pone.0202512 (B2)

LIBERAL RODRIGO ET AL: "The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway", HEPATOLOGY, JOHN WILEY & SONS, INC., US, vol. 56, no. 2, 1 August 2012 (2012-08-01), US, pages 677 - 686, ISSN: 0270-9139, DOI: 10.1002/hep.25682 (B2)

MCMURCHY ET AL.: "Suppression assays with human T regulatory cells: A technical guide", EUR. J. IMMUNOL., vol. 42, no. 1, 2012, pages 27 - 34, DOI: 10.1002/eji.201141651 (B2)

MOUGLAKAKOS DIMITRIOS, ET AL: "Regulatory T Cells in Cancer", ADVANCES IN CANCER RESEARCH, vol. 107, 1 January 2010 (2010-01-01), pages 57 - 117 (B2)

NOBUMOTO A., ET AL: "Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices", GLYCOBIOLOGY, OXFORD UNIVERSITY PRESS, US, vol. 18, no. 9, 1 January 2008 (2008-01-01), US, pages 735 - 744, ISSN: 0959-6658, DOI: 10.1093/glycob/cwn062 (B2)

NPC xenograft experiments with antibodies 1G3 and 2E12 in mouse (B2)

Poster by Margall II (B2)

Proliferation experiments with anti- Gal -9 antibodies (B2)

RABINOVICH ET AL.: "Regulatory Circuits Mediated by Lectin-Glycan Interactions in Autoimmunity and Cancer", IMMUNITY, vol. 36, no. 3, 2012, pages 322 - 35, DOI: 10.1016/j.immuni.2012.03.004 (B2)

RABINOVICH G. A., LIU F.-T., HIRASHIMA M., ANDERSON A.: "An Emerging Role for Galectins in Tuning the Immune Response: Lessons from Experimental Models of Inflammatory Disease, Autoimmunity and Cancer", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENCE PUBL., OXFORD, GB, vol. 66, no. 2-3, 1 August 2007 (2007-08-01), GB, pages 143 - 158, ISSN: 0300-9475, DOI: 10.1111/j.1365-3083.2007.01986.x (B2)

SAKAGUCHI: "Naturally arising Foxp3-expressing CD 25+ CD 4+ regulatory T cells in immunological tolerance to self and non-self", NATURE IMMUNOLOGY, vol. 6, no. 4, 2005, pages 345 - 52, DOI: 10.1038/ni1178 (B2)

SAKAGUCHI: "Regulatory T Cells: Key Controllers of Immunologic Self- Tolerance", CELL, vol. 101, no. 5, 2000, pages 455 - 8, DOI: 10.1016/S0092-8674(00)80856-9 (B2)

SUN QIQING, ET AL: "Prognostic and diagnostic signifcance of galectins in pancreatic cancer: a systematic review and meta-analysis", CANCER CELL INTERNATIONAL, vol. 19, no. 309, 1 December 2019 (2019-12-01), pages 1 - 14, DOI: 10.1186/s12935-019-1025-5 (B2)

TAAMS ET AL.: "Human anergic/suppressive CD 4+ CD 25+ T cells: a highly differentiated and apoptosis-prone population", EUR. J. IMMUNOL., vol. 31, 2001, pages 1122 - 1131, DOI: 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P (B2)

Translation D27 (B2)

TÖPFER KATRIN ET AL: "Tumor Evasion from T Cell Surveillance", JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, vol. 2011, 1 January 2011 (2011-01-01), pages 1 - 19, ISSN: 1110-7243, DOI: 10.1155/2011/918471 (B2)

US-B2- 8 329 660 (B2)

WANG ET AL.: "Tim-3-Galectin-9 pathway involves the suppression induced by CD 4+ CD 25+ regulatory T cells", IMMUNOBIOLOGY, vol. 214, no. 5, 2009, pages 342 - 9, DOI: 10.1016/j.imbio.2008.10.007 (B2)

WANG KAI, CHEN ZHEN, WU RONGZU, YIN JUN, FAN MIN, XU XIANLIN: "Prognostic Role of High Gal-9 Expression in Solid Tumours: a Meta-Analysis", CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, KARGER BASEL, CH, vol. 45, no. 3, 1 January 2018 (2018-01-01), CH, pages 993 - 1002, ISSN: 1015-8987, DOI: 10.1159/000487294 (B2)

WO-A1-2016/073299 (B2)

WO-A1-2021/139682 (B2)

WO-A2-2014/144600 (B2)

WO-A1-2012/177788 (B1)